Hyperfine Inc (HYPR)vsNovartis AG ADR (NVS)
HYPR
Hyperfine Inc
$1.47
-8.00%
HEALTHCARE · Cap: $158.83M
NVS
Novartis AG ADR
$148.38
+2.99%
HEALTHCARE · Cap: $289.19B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 368991% more annual revenue ($56.58B vs $15.33M). NVS leads profitability with a 23.9% profit margin vs -226.9%. NVS earns a higher WallStSmart Score of 49/100 (D+).
HYPR
Avoid23
out of 100
Grade: F
NVS
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for HYPR.
Margin of Safety
-62.6%
Fair Value
$91.58
Current Price
$148.38
$56.80 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 82.6% year-over-year
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -101.2% — below average capital efficiency
Negative free cash flow — burning cash
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : HYPR
The strongest argument for HYPR centers on Revenue Growth. Revenue growth of 82.6% demonstrates continued momentum.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : HYPR
The primary concerns for HYPR are EPS Growth, Market Cap, Return on Equity.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Key Dynamics to Monitor
HYPR profiles as a hypergrowth stock while NVS is a declining play — different risk/reward profiles.
HYPR carries more volatility with a beta of 1.42 — expect wider price swings.
HYPR is growing revenue faster at 82.6% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (49/100 vs 23/100), backed by strong 23.9% margins. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Hyperfine Inc
HEALTHCARE · MEDICAL DEVICES · USA
Hyperfine Inc. is a leading medical technology innovator that has revolutionized imaging diagnostics with the introduction of the first FDA-cleared portable MRI system. This groundbreaking solution enhances accessibility to imaging directly at the point of care, thereby improving patient outcomes and expediting clinical decision-making. By prioritizing cost efficiency and convenience, Hyperfine is well-positioned to capitalize on burgeoning market opportunities, making it an appealing investment for institutional investors interested in transformative healthcare advancements.
Visit Website →Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?